SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.31), $0.05 better than the analyst estimate of ($0.36).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.